Research
Hormonal
Time-restricted feeding (TRF) that aligns food intake with circadian rhythms (e.g., restricting eating to 8-12 hours during the day) improves metabolic health, including weight loss, insulin sensitivity, and lipid profiles, independent of caloric restriction.
Restrict your eating to an 8-12 hour window each day, ideally finishing dinner early and skipping late-night snacks. This aligns with your body's natural circadian rhythms, improving insulin sensitivity and potentially aiding weight loss, even if you don't count calories.
ModerateSupportsMEDIUM confidence
Interestingly, mice whose HFD feeding was restricted to 8 hours during the normal nocturnal eating time consumed equivalent energy, but were protected from obesity, hyperinsulinemia, hepatic steatosis, and inflammation compared with ad libitum HFD-fed mice (47).
Why this rating
Strong animal data, but human studies are described as having modest sample sizes and mixed results.
Source
Metabolic Effects of Intermittent Fasting
Ruth E. Patterson et al. · Annual Review of Nutrition · 2017
DOI 10.1146/annurev-nutr-071816-064634
narrative_reviewCited 800×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Prolonging the nightly fasting interval (≥11-13 hours) is associated with reduced odds of elevated HbA1c, lower inflammatory markers, and reduced breast cancer recurrence risk.Good
- Alternate-day fasting (ADF) and modified fasting (e.g., 5:2 diet) result in weight loss comparable to continuous energy restriction, with mixed effects on metabolic biomarkers.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →